UPDATE 2-Higher dose of Gilead-Galapagos drug meets ulcerative colitis study goals

Gilead Sciences Inc and partner Galapagos NV said on Wednesday only a higher dose of their experimental drug filgotinib showed greater effectiveness than placebo in a pivotal study testing it in ulcerative colitis patients. Filgotinib is also in advanced stages of testing against multiple types of inflammatory conditions including rheumatoid arthritis, a market dominated by drugs such as AbbVie's Humira.

from Reuters: Company News https://ift.tt/36iHB9B
via IFTTT